文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

伴嗜酸性粒细胞增多的髓系肿瘤

Myeloid neoplasms with eosinophilia.
PubMed 文献 · Blood · 2016-12-27

分子诊断进展揭示了伴嗜酸性粒细胞增多的髓系肿瘤的遗传学基础,世界卫生组织(WHO)将PDGFRA、PDGFRB、FGFR1重排或PCM1-JAK2融合定义的疾病归为一类,伊马替尼显著改变了PDGFRA和PDGFRB重排肿瘤的自然史,而FGFR1和JAK2融合患者病程更具侵袭性且对当前酪氨酸激酶抑制剂敏感性不一,多数需异基因造血干细胞移植才可能长期无病生存。

要点

  • WHO分类将伴嗜酸性粒细胞增多及PDGFRA、PDGFRB、FGFR1重排或PCM1-JAK2的髓系/淋系肿瘤归为一类。
  • PDGFRA和PDGFRB重排肿瘤的自然史因伊马替尼而显著改变。
  • FGFR1和JAK2融合患者病程更具侵袭性,多数需异基因造血干细胞移植才可能长期无病生存。

核心结论

  • 伴嗜酸性粒细胞增多的髓系肿瘤由融合酪氨酸激酶基因失调驱动,PDGFRA和PDGFRB重排者对伊马替尼敏感,而FGFR1和JAK2融合者病程更具侵袭性且对当前酪氨酸激酶抑制剂敏感性不一,多数需异基因造血干细胞移植才可能长期无病生存。

研究设计与样本

  • 综述,讨论伴嗜酸性粒细胞增多的髓系肿瘤的分子诊断、WHO分类及治疗。

主要发现

  • WHO分类将伴PDGFRA、PDGFRB或FGFR1重排或PCM1-JAK2的髓系/淋系肿瘤归为一类,患者可表现为骨髓增殖性肿瘤、骨髓增生异常综合征/骨髓增殖性肿瘤以及原发或继发性混合表型白血病或淋巴瘤。
  • 嗜酸性粒细胞增多是这些疾病的常见特征,但并非不变的特征。
  • PDGFRA和PDGFRB重排肿瘤的自然史因伊马替尼而显著改变。
  • FGFR1和JAK2融合酪氨酸激酶基因患者病程更具侵袭性且对当前酪氨酸激酶抑制剂敏感性不一,多数需异基因造血干细胞移植才可能长期无病生存。
  • FLT3或ABL1重排(两者常与ETV6伙伴)可能观察到相似的预后不良结局,需进一步研究以验证其纳入当前WHO定义的嗜酸性粒细胞相关酪氨酸激酶融合驱动肿瘤组。

关键数值与推荐

  • 慢性嗜酸性粒细胞白血病,非特指型(CEL, NOS)的诊断分配给伴有嗜酸性粒细胞增多及非特异性细胞遗传学/分子学异常和/或骨髓原始细胞增多的骨髓增殖性肿瘤患者。
  • 髓系突变面板已在暂定为意义未明的高嗜酸性粒细胞增多症患者中识别体细胞变异,将其中部分病例重新分类为嗜酸性粒细胞相关肿瘤。

局限性

  • 需进一步研究以验证FLT3或ABL1重排纳入当前WHO定义的嗜酸性粒细胞相关酪氨酸激酶融合驱动肿瘤组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular diagnostics has generated substantial dividends in dissecting the genetic basis of myeloid neoplasms with eosinophilia. The family of diseases generated by dysregulated fusion tyrosine kinase (TK) genes is recognized by the World Health Organization (WHO) category, "Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2" In addition to myeloproliferative neoplasms (MPN), these patients can present with myelodysplastic syndrome/MPN, as well as de novo or secondary mixed-phenotype leukemias or lymphomas. Eosinophilia is a common, but not invariable, feature of these diseases. The natural history of PDGFRA- and PDGFRB-rearranged neoplasms has been dramatically altered by imatinib. In contrast, patients with FGFR1 and JAK2 fusion TK genes exhibit a more aggressive course and variable sensitivity to current TK inhibitors, and in most cases, long-term disease-free survival may only be achievable with allogeneic hematopoietic stem cell transplantation. Similar poor prognosis outcomes may be observed with rearrangements of FLT3 or ABL1 (eg, both of which commonly partner with ETV6), and further investigation is needed to validate their inclusion in the current WHO-defined group of eosinophilia-associated TK fusion-driven neoplasms. The diagnosis chronic eosinophilic leukemia, not otherwise specified (CEL, NOS) is assigned to patients with MPN with eosinophilia and nonspecific cytogenetic/molecular abnormalities and/or increased myeloblasts. Myeloid mutation panels have identified somatic variants in patients with a provisional diagnosis of hypereosinophilia of undetermined significance, reclassifying some of these cases as eosinophilia-associated neoplasms. Looking forward, one of the many challenges will be how to use the results of molecular profiling to guide prognosis and selection of actionable therapeutic targets.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2016. PMID: 28028030. doi:10.1182/blood-2016-10-695973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。